Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.

Xinrong ZhangGrace Lai-Hung WongTerry Cheuk-Fung YipYee-Kit TseLilian Yan LiangVicki Wing-Ki HuiHuapeng LinGuan-Lin LiJimmy Che-To LaiHenry Lik-Yuen ChanVincent Wai-Sun Wong

Published in: Hepatology (Baltimore, Md.) (2022)

ACEI, rather than ARB, treatment is associated with a lower risk of LREs in NAFLD patients, especially among those with CKD.

Keyphrases

angiotensin converting enzyme
end stage renal disease
chronic kidney disease
angiotensin ii
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
drug induced